Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

costs and expenses for the 2013 period was primarily attributable to the timing of educational and marketing programs, combined with lower personnel costs for the company's hospital sales specialists. These reductions were partially offset by higher legal expenses incurred during the 2013 period related to the company's intellectual property litigation.

As of March 31, 2013, Cadence held cash, cash equivalents and short-term investments of $64.2 million, an increase of $2.1 million from the $62.1 million at December 31, 2012. Net accounts receivable at March 31, 2013, was $8.9 million.

GuidanceAs of May 2, 2013, Cadence is increasing its guidance to reflect the impact of the deferred revenue recognized in the first quarter of 2013. It now expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from approximately $97.0 million to $103.0 million.

Conference Call and Webcast on May 2, 2013 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Cadence management will host a conference call on May 2, 2013, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.

About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 1
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 2014 The National Model Aviation Museum, ... is pleased to announce that it has been granted ... the United States Air Force. , The certification is ... concluded this spring with an on-site inspection by Sarah ... , The National Museum of the United States ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... U.S. subsidiary in Philadelphia Area -, PHILADELPHIA, ... in,vivo cellular imaging, announced today the appointment of ... U.S. subsidiary of Paris-based Mauna,Kea Technologies and develops ... which improves patient care by eliminating the,need for ...
... used to provide cost-efficient, easy to use ... collecting lung sputum samples for testing, ALBUQUERQUE, N.M., ... maker of patented early lung cancer detection,testing and other ... Acoustics, LLC, to collect lung sputum,samples in an upcoming ...
... be presented at AACR ... on Cancer Stem Cells -, TORONTO, Feb. 13 /PRNewswire-FirstCall/ ... developing the next wave of,antibody therapeutics, today announced that new ... antibody will be,presented at the AACR Special Conference on Cancer ...
Cached Biology Technology:Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans 2Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 4
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... Ariz. Humans are having an effect on Earth,s ecosystems ... warming of the planet we are causing. Now you can ... leaving behind. The only question is how large of an ... the current issue of Science (Dec. 16, 2011), ...
... Austen BioInnovation Institute in Akron (ABIA) and the U.S. ... ground-breaking collaboration to support and develop regulatory science for ... devices. Effective today, the FDA and ABIA executed ... to draw upon ABIA resourcesincluding a library of test ...
... 2011. Monitored by scientists at Kessler Foundation, six people with ... Ekso Bionics that enables wheelchair users to stand and walk. ... in October 2011. Five patients have paraplegia and one ... and had durations of injury from 4 months to 2 ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2